Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 76 AL 90

Masitinib for the treatment of mild to moderate Alzheimer's disease

Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A.

Expert Rev Neurother. 2015 Jun;15(6):587-96. doi: 10.1586/14737175.2015.1045419. Epub 2015 May 11.

Drug repositioning in Alzheimer's disease

Corbett A, Williams G, Ballard C.

Front Biosci (Schol Ed). 2015 Jun 1;7(1):184-8. doi: 10.2741/S432.

Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer's Disease

Faldu KG, Shah JS, Patel SS.

Recent Pat Antiinfect Drug Discov. 2015;10(2):76-83. doi: 10.2174/1574891x10666150509193236.

Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease

Ajith TA, Padmajanair G.

Curr Aging Sci. 2015;8(3):235-40. doi: 10.2174/187460980803151027115147.

New cardiovascular targets to prevent late onset Alzheimer disease

Claassen JA.

Eur J Pharmacol. 2015 Sep 15;763(Pt A):131-4. doi: 10.1016/j.ejphar.2015.05.022. Epub 2015 May 15.

Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer's Disease

Cheung TS, Song TH, Ng TB, Wu FH, Lao LX, Tang SC, Ho JC, Zhang KY, Sze SC.

Curr Med Chem. 2015;22(19):2392-403. doi: 10.2174/0929867322666150520095509.

Impaired mitochondrial energy metabolism in Alzheimer's disease: Impact on pathogenesis via disturbed epigenetic regulation of chromatin landscape

Salminen A, Haapasalo A, Kauppinen A, Kaarniranta K, Soininen H, Hiltunen M.

Prog Neurobiol. 2015 Aug;131:1-20. doi: 10.1016/j.pneurobio.2015.05.001. Epub 2015 May 19.

A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers

Boinpally R, Chen L, Zukin SR, McClure N, Hofbauer RK, Periclou A.

Clin Drug Investig. 2015 Jul;35(7):427-35. doi: 10.1007/s40261-015-0296-4.

Editorial: Small molecule therapeutics for Alzheimer's disease

Ma DL, Leung CH.

Curr Alzheimer Res. 2015;12(5):400-2. doi: 10.2174/156720501205150526115737.

Statins for Treating Alzheimer's Disease: Truly Ineffective?

Liang T, Li R, Cheng O.

Eur Neurol. 2015;73(5-6):360-6. doi: 10.1159/000382128. Epub 2015 May 28.

Idalopirdine as a treatment for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2015;24(7):981-7. doi: 10.1517/13543784.2015.1052402. Epub 2015 May 28.

Multiple Ligands Targeting Cholinesterases and β-Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore

Szałaj N, Bajda M, Dudek K, Brus B, Gobec S, Malawska B.

Arch Pharm (Weinheim). 2015 Aug;348(8):556-63. doi: 10.1002/ardp.201500117. Epub 2015 May 29.

Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease

Kumar A, Sharma V, Singh VP, Kaundal M, Gupta MK, Bariwal J, Deshmukh R.

Mech Ageing Dev. 2015 Jul;149:75-87. doi: 10.1016/j.mad.2015.05.009. Epub 2015 Jun 4.

Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: a comprehensive review

Venkatesan R, Ji E, Kim SY.

Biomed Res Int. 2015;2015:814068. doi: 10.1155/2015/814068. Epub 2015 May 14.

Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US

Saint-Laurent Thibault C, Özer Stillman I, Chen S, Getsios D, Proskorovsky I, Hernandez L, Dixit S.

J Med Econ. 2015;18(11):930-43. doi: 10.3111/13696998.2015.1063501. Epub 2015 Aug 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias